Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 9/20 | 0.57 |
| ▸ | CDK2 | P24941 | 8/20 | 0.57 |
| ▸ | ROCK1 | Q13464 | 9/20 | 0.54 |
| ▸ | LCK | P06239 | 2/20 | 0.45 |
| ▸ | KDR | P35968 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | PRKCI | P41743 | 1/20 | 0.43 |
| ▸ | MAP3K14 | Q99558 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27985116 | 0.80 | CDK2 (0.53) | CDC7CDK2ROCK1LCK | |
| SCHEMBL3304129 | 0.79 | CDC7 (0.56) | CDC7CDK2ROCK1LCKKDR | |
| SCHEMBL16610260 | 0.75 | CDC7 (0.59) | CDC7CDK2ROCK1MAPTMAP3K14 | |
| SCHEMBL20784111 | 0.73 | MAPT (0.48) | CDC7CDK2ROCK1MAPTPRKCI | |
| SCHEMBL31735499 | 0.73 | MAPT (0.48) | CDC7CDK2ROCK1MAPTPRKCI | |
| SCHEMBL3304258 | 0.72 | PSEN1 (0.47) | CDC7CDK2ROCK1KDR | |
| SCHEMBL31735741 | 0.71 | MAPT (0.57) | CDC7CDK2ROCK1MAPTPRKCI | |
| SCHEMBL12821409 | 0.70 | ROCK1 (1.00) | CDC7CDK2ROCK1MAP3K14 | |
| SCHEMBL16862178 | 0.70 | CDC7 (0.54) | CDC7CDK2ROCK1MAPTPRKCI | |
| SCHEMBL31735756 | 0.70 | PRKCI (0.49) | CDC7CDK2ROCK1MAPTPRKCI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2121600-B1 | SUBSTITUTED ARYLSULPHONYLGLYCINES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INT (DE) | 2012-07-18 | — | — | EP | disclosed |
| US-20100093703-A1 | SUBSTITUTED ARYLSULPHONYLGLYCINES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-15 | — | — | US | disclosed |
| US-20100093703-A1 | SUBSTITUTED ARYLSULPHONYLGLYCINES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-15 | — | — | US | disclosed |
| US-20100093703-A1 | SUBSTITUTED ARYLSULPHONYLGLYCINES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093703-A1 | SUBSTITUTED ARYLSULPHONYLGLYCINES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS | PYGL, PYGM, G6PC1 | CDC7 4322/4885CDK2 876/4885ROCK1 712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.